4th Quarter - Report
ZYLA LIFE SCIENCES (FKA EGALET CORPORATION) for ZYLA LIFE SCIENCES (FKA EGALET CORPORATION)
Income
—
Expenses
$143,000
Expense method
C: businesses, Internal Revenue Code section 162(e)
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Prescription drug abuse and misuse policy issues H.R. 2335 (114th Congress), provisions related to approval of abuse-deterrent opioids Abuse-deterrent opioid policy issues Pain therapy access policy issues
| Lobbyist | Covered position, as disclosed |
|---|---|
| CARA D MOON | — |
Medicare/Medicaid MMM
Prescription drug abuse policy issues Provisions related to abuse-deterrent opioid formulary placement Provisions related to abuse-deterrent opioid coverage and access in Medicare
| Lobbyist | Covered position, as disclosed |
|---|---|
| CARA D MOON | — |
Alcohol and Drug Abuse ALC
S. 524 (114th Congress): Provisions related to opioid treatment and abuse
| Lobbyist | Covered position, as disclosed |
|---|---|
| CARA D MOON | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.